MARKET

LEGN

LEGN

Legend Biotech Corp
NASDAQ
18.54
-1.00
-5.12%
After Hours: 18.93 +0.39 +2.09% 19:53 11/12 EST
OPEN
19.10
PREV CLOSE
19.54
HIGH
19.13
LOW
17.86
VOLUME
4.45M
TURNOVER
--
52 WEEK HIGH
37.50
52 WEEK LOW
16.24
MARKET CAP
3.61B
P/E (TTM)
-605.8824
1D
5D
1M
3M
1Y
5Y
1D
Legend Biotech (LEGN) Could Be 57% Undervalued On Profitability And CARVYKTI Growth
Simply Wall St · 19h ago
Legend Biotech Is Maintained at Perform by Oppenheimer
Dow Jones · 1d ago
Legend Biotech Price Target Cut to $25.00/Share From $40.00 by Oppenheimer
Dow Jones · 1d ago
Oppenheimer Maintains Perform on Legend Biotech, Lowers Price Target to $25
Benzinga · 1d ago
Legend Biotech Price Target Cut to $43.00/Share From $49.00 by Morgan Stanley
Dow Jones · 1d ago
Legend Biotech Is Maintained at Overweight by Morgan Stanley
Dow Jones · 1d ago
Morgan Stanley Maintains Overweight on Legend Biotech, Lowers Price Target to $43
Benzinga · 1d ago
Legend Biotech Price Target Cut to $61.00/Share From $68.00 by Barclays
Dow Jones · 1d ago
More
About LEGN
Legend Biotech Corporation is a global biopharmaceutical company. The Company is engaged in the discovery, development, manufacturing and commercialization of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.

Webull offers Legend Biotech Corp (ADR) stock information, including NASDAQ: LEGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LEGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LEGN stock methods without spending real money on the virtual paper trading platform.